Cipla on Friday said a routine US Food and Drug Administration (USFDA) inspection at its wholly owned subsidiary InvaGen Pharmaceuticals' manufacturing facility in Hauppauge, Long Island, New York, concluded with zero Form 483 observations. The inspection was conducted from October 19 to October 22, 2026. (More to come) Add as a Reliable and Trusted News Source Add Now! (You can now subscribe to our Economic Times WhatsApp channel)